Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Royo-Cebrecos, C.
39  Ergebnisse:
Personensuche X
?
1

Co-infections and superinfections complicating COVID-19 in ..:

Gudiol, C. ; Durà-Miralles, X. ; Aguilar-Company, J....
Journal of Infection.  83 (2021)  3 - p. 306-313 , 2021
Link: https://doi.org/10.1016/..
 
?
2

Administration of taurolidine-citrate lock solution for pre..:

Gudiol, C. ; Nicolae, S. ; Royo-Cebrecos, C....
Trials.  19 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
?
3

Bloodstream infection in patients with head and neck cancer..:

Marín, M. ; Gudiol, C. ; Castet, F....
Clinical and Translational Oncology.  21 (2018)  2 - p. 187-196 , 2018
Link: https://doi.org/10.1007/..
 
?
4

Characteristics, aetiology, antimicrobial resistance and ou..:

Royo-Cebrecos, C. ; Gudiol, C. ; García, J....
Journal of Infection.  74 (2017)  2 - p. 172-178 , 2017
Link: https://doi.org/10.1016/..
 
?
5

Clinical efficacy of β-lactam/β-lactamase inhibitor combina..:

Gudiol, C ; Royo-Cebrecos, C ; Tebe, C...
BMJ Open.  7 (2017)  1 - p. e013268 , 2017
Link: https://doi.org/10.1136/..
 
?
6

Pseudomonas aeruginosa Bloodstream Infections in Patients w..:

Royo-Cebrecos, C ; Laporte-Amargós, J ; Peña, M...
info:eu-repo/semantics/altIdentifier/doi/10.3390/pathogens11101132.  , 2022
Link: https://serval.unil.ch/n..
 
?
7

Co-infections and superinfections complicating COVID-19 in ..:

Gudiol, C ; Durà-Miralles, X ; Aguilar-Company, J...
http://hdl.handle.net/10668/18256.  , 2021
Link: http://hdl.handle.net/10..
 
?
8

Co-infections and superinfections complicating COVID-19 in ..:

Gudiol, C ; Durà-Miralles, X ; Aguilar-Company, J...
info:eu-repo/semantics/altIdentifier/pmid/34302864.  , 2021
Link: http://hdl.handle.net/11..
 
?
9

Administration of taurolidine-citrate lock solution for pre..:

Gudiol, C ; Nicolae, S ; Royo-Cebrecos, C...
http://hdl.handle.net/10668/12414.  , 2018
Link: http://hdl.handle.net/10..
 
?
10

Clinical efficacy of β-lactam/β-lactamase inhibitor combina..:

Gudiol, C ; Royo-Cebrecos, C ; Tebe, C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278288/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
11

Clinical efficacy of β-lactam/β-lactamase inhibitor combina..:

Gudiol, C ; Royo-Cebrecos, C ; Tebe, C...
http://hdl.handle.net/10668/10798.  , 2017
Link: http://hdl.handle.net/10..
 
?
12

Clinical Efficacy Of Beta-Lactam/Beta-Lactamase Inhibitor C..:

Gudiol, C ; Royo-Cebrecos, C ; Tebe, C...
10.1136/bmjopen-2016-013268.  , 2017
Link: http://hdl.handle.net/11..
 
?
13

Clinical efficacy of beta-lactam/beta-lactamase inhibitor c..:

Clemente, W. T ; Montejo, M ; Peghin, M...
8902adba-6899-4a9d-95c8-2f92b560761c.  , 2017
Link: https://doi.org/10.1136/..
 
?
14

Clinical efficacy of β-lactam/β-lactamase inhibitor combina..:

Gudiol, C ; Royo-Cebrecos, C ; Tebe, C...
http://bmjopen.bmj.com/content/7/1/e013268.long.  , 2017
Link: http://hdl.handle.net/10..
 
?
15

Pseudomonas aeruginosa bloodstream infections in patients w..:

Royo-Cebrecos, C. (Cristina) ; Laporte-Amargos, J. (J.) ; Pena, M. (Marta)...
https://pubmed.ncbi.nlm.nih.gov/36297188/.  , 2022
Link: https://hdl.handle.net/1..
 
1-15